Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Rgenix

Rgenix
2010 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$40M LATEST DEAL AMOUNT
12 INVESTORS
Description

Developer of novel cancer drugs that target key pathways in cancer progression. The company's therapies identify novel cancer targets using a microRNA based target discovery platform, enabling cancer patients to get faster cure using drugs that target using small molecules and antibodies.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 310 East 67th Street
  • Suite 1-12
  • New York, NY 10065
  • United States

+1 (646) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Rgenix’s full profile, request a free trial.

Rgenix Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 09-Oct-2018 $40M 000.00 00000 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 03-Jun-2016 0000 000.00 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 31-Jul-2015 000 000.00 000.00 Completed Pre-Clinical Trials
2. Grant 11-Aug-2014 $200K $2.5M Completed Pre-Clinical Trials
1. Seed Round 30-Sep-2013 $2.5M $2.5M 000.00 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Rgenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 13,889,841 $0.000100 $0.61 $0.61 1x $0.61 6.77%
Seed 5,869,618 $0.000100 $0.53 $0.53 1x $0.53 3.1%
To view this company’s complete Cap Table, request access »

Rgenix Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lycera Venture Capital-Backed Ann Arbor, MI 00 00000 00000000000 00000
0 00000 000000 Accelerator/Incubator Backed Houston, TX 000 000000000000 000
000000 00000000000 Venture Capital-Backed New York, NY 0000 00000000000 0000
000000 00000000 Formerly VC-backed Boulder, CO 000 00000 000000 - 000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
To view this company’s complete list of competitors, request access »

Rgenix Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Lepu Medical Corporation Minority 000 0000 000000 0
Oceanpine Capital Venture Capital Minority 000 0000 000000 0
Oceanpine Healthcare Fund Venture Capital Minority 000 0000 000000 0
WuXi AppTec Corporation Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Rgenix Executive Team (14)

Name Title Board
Seat
Contact
Info
Masoud Tavazoie Ph.D Co-Founder, Board Member and Chief Executive Officer
Sohail Tavazoie Ph.D Co-Founder, Scientific & Clinical Advisor
Michael Szarek Ph.D Vice President, Clinical & Regulatory Affairs
Foster Gonsalves Ph.D Vice President, Drug Development & Strategy
Steven Wald Vice President of Chemistry & Pharmaceutical Sciences

2 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Rgenix Board Members (10)

Name Representing Role Since Contact
Info
Antoine Papiernik Sofinnova Partners Board Member 000 0000
David Darst Self Chief Operating Officer & Board Observer 000 0000
Eric Rowinsky MD Self Board Member & President 000 0000
Masoud Tavazoie Ph.D Rgenix Co-Founder, Board Member and Chief Executive Officer 000 0000
Nancy Chang Ph.D Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 10 board members. Get the full list »